Pancreatic CancerPhase 4SPARROWNCT05784311
Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)
A Phase 4 study testing Cefuroxime and Metronidazole in people with Pancreatic Cancer, run by Leiden University Medical Center at 11 sites in Netherlands.
Trial summary
The goal of this multicenter randomized controlled trial is to evaluate the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Pancreatic Cancer
- What is being tested?
- Cefuroxime and Metronidazole
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 344 participants
- Where
- 11 sitesNetherlands
- Study dates
- 6 Mar 2023to Jan 2026
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients undergoing elective pancreatoduodenectomy with a high risk for contaminated bile defined as patients with preoperative biliary drainage or an ampullary malignancy.
- Age >18 years
Who cannot join
- Pregnancy
- Contraindication for the study antibiotics (e.g. allergy or intolerance)
- Preoperative planned therapeutic antibiotic treatment (i.e. for cholangitis or liver abscesses)
- A reduced renal function, defined as an eGFR of <60 ml/min/1.73m2 measured on the closest timepoint prior to pancreatoduodenectomy
Trial locations and contacts
11 sites in 1 country.
11 sites in 1 country
Netherlands11 sites, 11 recruiting
- Not yet recruiting
Jeroen Bosch Ziekenhuis
's-Hertogenbosch
Koop Bosscha, MD
- Recruiting
Amsterdam University Medical Center
Amsterdam
Marc GH Besselink, Prof. Dr
Marc GH Besselink, Prof. Dr.
- Recruiting
Amphia Ziekenhuis
Breda
Jan H Wijsman, MD PhD
- Recruiting
Catharina Ziekenhuis
Eindhoven
Misha DP Luyer, MD PhD
- Recruiting
Medisch Spectrum Twente
Enschede
Daan J Lips, MD PhD
- Recruiting
Groningen University Medical Center
Groningen
Frederik JH Hoogwater, MD PhD
- Recruiting
Leiden University Medical Center
Leiden, South Holland, 2333 ZA
Daphne HM Droogh, MD, 071 5261334, d.h.m.droogh@lumc.nl
Daphne HM Droogh, MD
- Recruiting
Maastricht University Medical Center
Maastricht
Stefan AW Bouwense, MD PhD
- Recruiting
Radboud University Medical Center
Nijmegen
Martijn Stommel, MD PhD
- Recruiting
Erasmus MC Cancer Institute
Rotterdam
Bas Groot Koerkamp, Prof. Dr.
- Recruiting
Regional Academic Cancer Center Utrecht
Utrecht
Hjalmar C van Santvoort, Prof. Dr
Hjalmar C van Santvoort, Prof. Dr.
About this study
Official title: Standard Versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes After Whipple's Procedure (SPARROW): a Multicenter, Randomized Controlled Trial
The goal of this multicenter randomized controlled trial is to evaluate the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile. The main objectives it aims to answer are:
- To evaluate the effect of pre-emptive antibiotic prophylaxis on clinically relevant OSIs in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile
- To evaluate the effect of pre-emptive antibiotic prophylaxis on other postoperative outcomes (e.g. OSIs, superficial SSIs, POPF, PPH, major morbidity, ICU admission, readmission, length of hospital stay, and mortality).
- To evaluate concordance between perioperatively obtained bile cultures and postoperative cultures from infectious sites, and to evaluate antibiotic sensitivity patterns of the cultured microorganisms.
Read more
Participants will be randomized with a 1:1 allocation before surgery into the intervention or control group:
- Patients in the intervention group will receive perioperative prophylaxis (similar to the control group) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily.
- Patients in the control group will only receive perioperative prophylaxis (a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4h of surgery), which will be discontinued after surgery.
Read the detailed description
Rationale: The additional value of pre-emptive antibiotic treatment after pancreatoduodenectomy is undetermined as previous research reported conflicting results regarding infectious complications. Prolonged antibiotic prophylaxis (formally pre-emptive antibiotic treatment) after pancreatoduodenectomy might reduce the rate of surgical site infections in patients with a high risk for contaminated bile (predominantly patients with preoperative biliary drainage or an ampullary malignancy). Current national and international guidelines lack clear recommendations regarding pre-emptive antibiotic treatment leading to substantially varying antibiotic prophylactic regimes between institutes.
Objective: This trial evaluates the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile.
Study design: This multicenter, randomized controlled, superiority trial compares perioperative versus pre-emptive antibiotic treatment during five postoperative days after pancreatoduodenectomy in patients with a high risk for contaminated bile.
Study population: Adult patients undergoing pancreatoduodenectomy with a high risk for contaminated bile (patients with preoperative biliary drainage or an ampullary malignancy). Patients with a contraindication for the study antibiotics or a preoperative indication for antibiotics (e.g. cholangitis of preoperative abscesses) are excluded.
Intervention: Participants will be randomized to either perioperative prophylaxis (cefazolin, metronidazole and a single dose of 5-7mg/kg gentamicin, control arm) or additional cefuroxime and metronidazole for five postoperative days (experimental arm).
Main study endpoints: The primary endpoint are organ/space infections (OSIs) within 90 days after surgery requiring a therapeutic intervention. Secondary endpoints are OSIs, isolated OSIs, wound infections, postoperative pancreatic fistula, bile or enteric anastomotic leakage, post pancreatectomy hemorrhage, delayed gastric emptying, bacteremia, Clostridium difficile infection, major morbidity (Clavien-Dindo ≥III), reintervention, ICU admission, length of hospital stay, readmission, and in-hospital and 90-day mortality. Besides, switch of postoperative antibiotics, antibiotic sensitivity patterns and concordance between perioperative bile and postoperative surgical site cultures are analyzed.
Sample size: The sample size is calculated for superiority to achieve an OSI difference of 15% (40% vs 25%). With a 80% power (1-β) and a two-sided significance level (α) of 5.0%, a sample of 304 evaluable patients is required for superiority. Assuming a 3% non-resection rate due to metastatic disease and a 3% loss-of-follow-up rate, an expected number of 322 included patients are needed to reach the sample size of 304 evaluable patients to demonstrate superiority for the intervention.
- Conditions
- Pancreatic Cancer
- Being tested
- Cefuroxime, Metronidazole
- Keywords
- Antibiotic prophylaxis, Preoperative biliary drainage, Surgical site infection
- Medical subject headings
- Pancreatic Neoplasms, Surgical Wound Infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CefuroximeDrug
Also called Zinacef
1500mg IV cefuroxime thrice daily during five days.
MetronidazoleDrug
Also called Flagyl
500mg IV metronidazole thrice daily during five days.
| Study group | Role | What they receive |
|---|---|---|
| Perioperative plus prolonged antibiotic prophylaxis | Experimental | Prolonged prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery (perioperative prophylaxis) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily Receives: Drug: Cefuroxime; Drug: Metronidazole |
| Only perioperative prophylaxis | No intervention | Perioperative prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of clinically relevant organ/space surgical site infection (OSI) between patients with perioperative versus prolonged antibiotic prophylaxis
A clinically relevant OSI is defined by the following criteria:
- A deep surgical site infection involving any part of the abdomen (e.g. organs and/or spaces) other than the surgical incision within 90 days after surgery.
- AND Requires radiological, endoscopic or surgical intervention OR therapeutic antibiotics required for an episode of sepsis, defined as two or more SIRS criteria.
- AND Organisms isolated from an aseptically obtained culture.
Measured: 90 days after surgery
Secondary outcomes (15)
The rate of organ/Space Infection (OSI) between patients with perioperative versus prolonged antibiotic prophylaxis
An OSI is defined by the CDC definition:
- The infection appears to be related to the operative procedure and infection involves any part of the anatomy (e.g., organs or spaces) other than the incision opened or manipulated during the operative procedure, and at least one of the following is present:
- Purulent drainage from a drain that is placed into the organ/space.
- Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space.
- An abscess or other evidence of infection involving the organ/space on direct examination, during reoperation, or by histopathologic or radiologic examination.
- Diagnosis of an organ/space SSI by a surgeon or attending physician."
Measured: 90 days
The rate of isolated OSI between patients with perioperative versus prolonged antibiotic prophylaxis
Isolated OSI is defined as an OSI without concurrent anastomotic leakage (pancreatojejunostomy, hepaticojejunostomy or gastrojejunostomy). The concept of an isolated OSI is used to separately classify abdominal infections without concurrent anastomotic leakage.
Measured: 90 days
The rate of superficial incisional SSI between patients with perioperative versus prolonged antibiotic prophylaxis
A superficial surgical site infection after surgery which involves superficial or deep soft tissue (skin, muscle or fascia, but no intra-abdominal tissue), and at least one of the following criteria is present:
- Purulent drainage from the incision or subcutaneous tissue.
- Isolation of microorganisms from an aseptically obtained culture of fluid or tissue from the superficial incision of subcutaneous tissue.
- Superficial infections of the skin or subcutaneous tissue which is deliberately opened by a surgeon or attending physician OR at least one of the following signs are present: localizes pain, tenderness, swelling, heat or fever >38 degrees).
Measured: 90 days
The rate of clinically relevant postoperative pancreatic fistula between patients with perioperative versus prolonged antibiotic prophylaxis
Grade B or C postoperative pancreatic fistula (POPF) defined by the International Study Group of Pancreatic Surgery definition:
Grade A: Amylase >3 times upper limit of the institutional normal serum amylase value
Grade B: Grade A + persistant drainage >3 weeks, clinically relevant change in management of POPF, percutaneous or endoscopic drainage, angiographic procedures for bleeding, or signs of infection without organ failure.
Grade C: Grade A or B requiring reoperation, resulting in organ failure or death.
Measured: 90 days
The rate of bile leakage between patients with perioperative versus prolonged antibiotic prophylaxis
Grade A, B or C defined by the ISGLS definition:
Grade A: Bile leakage requiring no or little change in patients' clinical management.
Grade B: Bile leakage requiring a change in patients clinical management (eg, additional diagnostic or interventional procedures) but manageable without relaparotomy, or a Grade A bile leakage lasting for >1 week.
Grade C: Bile leakage requiring relaparotomy
Measured: 90 days
The rate of post pancreatectomy hemorrhage between patients with perioperative versus prolonged antibiotic prophylaxis
Grade A, B or C defined by the ISGPS definition:
Grade A: Early (<24h after surgery), intra- or extraluminal, clinically mild.
Grade B: Early (<24h after surgery), intra- or extraluminal and clinically severe OR later (>24h after surgery), intra- or extraluminal and clincally mild.
Grade C: Late (>24h after surgery), intra- or extraluminal and clinically severe.
Measured: 90 days
The rate of delayed gastric emptying between patients with perioperative versus prolonged antibiotic prophylaxis
Grade A, B or C defined by the ISGPS definition:
Grade A: Until day 4-7 or replacement of feeding tube > 3 days after surgery
Grade B: Until day 8-14 or replacement of feeding tube > 7 days after surgery
Grade C: >day 14 or replacement of feeding tube > 14 after surgery
Measured: 90 days
The rate of postoperative bacteremia between patients with perioperative versus prolonged antibiotic prophylaxis
Defined as a positive blood culture obtained during a septic period (defined as two or more SIRS criteria)
Measured: 90 days
The rate of Clostridium difficile infection between patients with perioperative versus prolonged antibiotic prophylaxis
Defined by a positive fecal culture for Clostridium difficile
Measured: 90 days
Rate of major complications between patients with perioperative versus prolonged antibiotic prophylaxis
Major complications is defined by a Clavien-Dindo score of ≥III.
Clavien-Dindo classification of Surgical Complications:
Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions.
Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications.
Grade IIIa: Requiring surgical, endoscopic or radiological intervention not under general anesthesia Grade IIIb: Requiring surgical, endoscopic or radiological intervention under general anesthesia
Grade IVa: Life-threatening complication (including CNS complications)* requiring IC/ICU-management with single organ dysfunction (including dialysis).
Grade IVb: Life-threatening complication (including CNS complications)* requiring IC/ICU-management with multi organ dysfunction.
Grade V: Death of a patient
Measured: 90 days
The number of reinterventions in patients with perioperative versus prolonged antibiotic prophylaxis
Reinterventions could be either radiological, surgical or endoscopic reinterventions
Measured: 90 days
The number of ICU admission in patients with perioperative versus prolonged antibiotic prophylaxis
ICU admission
Measured: 90 days
Length of hospital stay in patients with perioperative versus prolonged antibiotic prophylaxis
In days
Measured: 90 days
The number of readmissions between patients with perioperative versus prolonged antibiotic prophylaxis
Readmission into the hospital
Measured: 90 days
Mortality
In-hospital and 90-days mortality
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2023
- Study start6 Mar 2023
- Primary completionJul 2025 (estimated)
- Study completionJan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by Leiden University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patients will be randomized with a 1:1 allocation before surgery into the intervention or control group: * Patients in the intervention group will receive perioperative prophylaxis (similar to the control group) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily. * Patients in the control group will only receive perioperative prophylaxis (a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4h of surgery), which will be discontinued after surgery.
- Masking
- None (open label)
- Enrolment
- 344 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Leiden University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, J.S.D. Mieog, MD PhD, Leiden University Medical Center
- Investigators
- J. Sven D. Mieog, MD PhD, Principal investigator, Leiden University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05784311
- Sponsor's protocol ID
- NL82304.058.22
- Acronym
- SPARROW
- Status last verified
- Oct 2024
- First submitted
- 27 Feb 2023
- Last updated
- 21 Oct 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Available upon request to the principal investigator
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Standard Versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes After Whipple's Procedure (SPARROW): a Multicenter, Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05784311
- Acronym / sponsor ID
- SPARROW / NL82304.058.22
- Conditions
- Pancreatic Cancer
- Keywords
- Antibiotic prophylaxis, Preoperative biliary drainage, Surgical site infection
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 344 participants (estimated)
- Lead sponsor
- Leiden University Medical CenterUniversity, hospital or other
- Study start
- 6 Mar 2023 (actual)
- Primary completion
- Jul 2025 (estimated)
- Study completion
- Jan 2026 (estimated)
- First posted
- 24 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this multicenter randomized controlled trial is to evaluate the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile. The main objectives it aims to answer are:
- To evaluate the effect of pre-emptive antibiotic prophylaxis on clinically relevant OSIs in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile
- To evaluate the effect of pre-emptive antibiotic prophylaxis on other postoperative outcomes (e.g. OSIs, superficial SSIs, POPF, PPH, major morbidity, ICU admission, readmission, length of hospital stay, and mortality).
- To evaluate concordance between perioperatively obtained bile cultures and postoperative cultures from infectious sites, and to evaluate antibiotic sensitivity patterns of the cultured microorganisms.
Participants will be randomized with a 1:1 allocation before surgery into the intervention or control group:
- Patients in the intervention group will receive perioperative prophylaxis (similar to the control group) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily.
- Patients in the control group will only receive perioperative prophylaxis (a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4h of surgery), which will be discontinued after surgery.
Detailed description
Rationale: The additional value of pre-emptive antibiotic treatment after pancreatoduodenectomy is undetermined as previous research reported conflicting results regarding infectious complications. Prolonged antibiotic prophylaxis (formally pre-emptive antibiotic treatment) after pancreatoduodenectomy might reduce the rate of surgical site infections in patients with a high risk for contaminated bile (predominantly patients with preoperative biliary drainage or an ampullary malignancy). Current national and international guidelines lack clear recommendations regarding pre-emptive antibiotic treatment leading to substantially varying antibiotic prophylactic regimes between institutes.
Objective: This trial evaluates the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile.
Study design: This multicenter, randomized controlled, superiority trial compares perioperative versus pre-emptive antibiotic treatment during five postoperative days after pancreatoduodenectomy in patients with a high risk for contaminated bile.
Study population: Adult patients undergoing pancreatoduodenectomy with a high risk for contaminated bile (patients with preoperative biliary drainage or an ampullary malignancy). Patients with a contraindication for the study antibiotics or a preoperative indication for antibiotics (e.g. cholangitis of preoperative abscesses) are excluded.
Intervention: Participants will be randomized to either perioperative prophylaxis (cefazolin, metronidazole and a single dose of 5-7mg/kg gentamicin, control arm) or additional cefuroxime and metronidazole for five postoperative days (experimental arm).
Main study endpoints: The primary endpoint are organ/space infections (OSIs) within 90 days after surgery requiring a therapeutic intervention. Secondary endpoints are OSIs, isolated OSIs, wound infections, postoperative pancreatic fistula, bile or enteric anastomotic leakage, post pancreatectomy hemorrhage, delayed gastric emptying, bacteremia, Clostridium difficile infection, major morbidity (Clavien-Dindo ≥III), reintervention, ICU admission, length of hospital stay, readmission, and in-hospital and 90-day mortality. Besides, switch of postoperative antibiotics, antibiotic sensitivity patterns and concordance between perioperative bile and postoperative surgical site cultures are analyzed.
Sample size: The sample size is calculated for superiority to achieve an OSI difference of 15% (40% vs 25%). With a 80% power (1-β) and a two-sided significance level (α) of 5.0%, a sample of 304 evaluable patients is required for superiority. Assuming a 3% non-resection rate due to metastatic disease and a 3% loss-of-follow-up rate, an expected number of 322 included patients are needed to reach the sample size of 304 evaluable patients to demonstrate superiority for the intervention.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Patients will be randomized with a 1:1 allocation before surgery into the intervention or control group: * Patients in the intervention group will receive perioperative prophylaxis (similar to the control group) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily. * Patients in the control group will only receive perioperative prophylaxis (a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4h of surgery), which will be discontinued after surgery.
| Arm | Type | Receives |
|---|---|---|
| Perioperative plus prolonged antibiotic prophylaxis | Experimental | Drug: Cefuroxime, Drug: MetronidazoleProlonged prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery (perioperative prophylaxis) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily |
| Only perioperative prophylaxis | No intervention | –Perioperative prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients undergoing elective pancreatoduodenectomy with a high risk for contaminated bile defined as patients with preoperative biliary drainage or an ampullary malignancy.
- Age >18 years
Key exclusion criteria (4 listed)
- Pregnancy
- Contraindication for the study antibiotics (e.g. allergy or intolerance)
- Preoperative planned therapeutic antibiotic treatment (i.e. for cholangitis or liver abscesses)
- A reduced renal function, defined as an eGFR of <60 ml/min/1.73m2 measured on the closest timepoint prior to pancreatoduodenectomy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CefuroximeAlso: Zinacef1500mg IV cefuroxime thrice daily during five days. | Drug | Perioperative plus prolonged antibiotic prophylaxis |
| MetronidazoleAlso: Flagyl500mg IV metronidazole thrice daily during five days. | Drug | Perioperative plus prolonged antibiotic prophylaxis |
Primary outcome
Rate of clinically relevant organ/space surgical site infection (OSI) between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days after surgery
A clinically relevant OSI is defined by the following criteria: * A deep surgical site infection involving any part of the abdomen (e.g. organs and/or spaces) other than the surgical incision within 90 days after surgery. * AND Requires radiological, endoscopic or surgical intervention OR therapeutic antibiotics required for an episode of sepsis, defined as two or more SIRS criteria. * AND Organisms isolated from an aseptically obtained culture.
15 secondary outcomes
The rate of organ/Space Infection (OSI) between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The rate of isolated OSI between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The rate of superficial incisional SSI between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The rate of clinically relevant postoperative pancreatic fistula between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The rate of bile leakage between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The rate of post pancreatectomy hemorrhage between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The rate of delayed gastric emptying between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The rate of postoperative bacteremia between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The rate of Clostridium difficile infection between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
Rate of major complications between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The number of reinterventions in patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The number of ICU admission in patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
Length of hospital stay in patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
The number of readmissions between patients with perioperative versus prolonged antibiotic prophylaxis
Time frame: 90 days
Mortality
Time frame: 90 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2024.
- Individual participant dataSharing planned: No. Available upon request to the principal investigator
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
J. Sven D. Mieog, MD PhD principal investigator
Leiden University Medical Center
11 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Cefuroxime and Metronidazole in people with Pancreatic Cancer, run by Leiden University Medical Center at 11 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Daphne HM Droogh, MD (071 5261334, d.h.m.droogh@lumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of clinically relevant organ/space surgical site infection (OSI) between patients with perioperative versus prolonged antibiotic prophylaxis (time frame: 90 days after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2024.